Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Exercise Intervention to Support Recovery After Allogeneic Stem Cell Transplantation in Adults With Myeloid Blood Disorders (RESTART)

17 de novembro de 2026 atualizado por: Miriam Götte, Universität Duisburg-Essen

RESTART - Cognitive, Physiological, and Immunological Effects of a Multimodal Exercise Intervention in Patients After Allogeneic Hematopoietic Stem Cell Transplantation

The goal of this clinical trial is to learn how a 12-week exercise intervention affects recovery after allogeneic stem cell transplantation in adults with a myeloid blood disorder. The main question is whether the exercise intervention helps maintain or improve thinking skills, especially attention, mental flexibility, and working memory, compared with usual care. The study will also look at physical function, quality of life, symptoms, activity levels, and clinical recovery.

After leaving the hospital following stem cell transplantation, participants will be randomly assigned to one of two groups. One group will receive the 12-week exercise intervention in addition to usual care. The other group will receive usual care without an additional RESTART exercise program during these 12 weeks.

Participants in the exercise group will complete three exercise sessions each week: one individual in-person session, one guided online session, and one home-based session.

The exercises may include endurance, strength, mobility, balance, coordination, and activities that combine movement with thinking tasks. The program will be adjusted to each participant's health, fitness, symptoms, and daily condition.

All participants will complete study assessments shortly before transplantation, at hospital discharge, and after the 12-week intervention or control period. Follow-up assessments will also take place 6 and 12 months after discharge, mainly using questionnaires and clinical information from routine care.

Visão geral do estudo

Status

Recrutamento

Condições

Intervenção / Tratamento

Tipo de estudo

Intervencional

Inscrição (Estimado)

80

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

Locais de estudo

    • North Rhine-Westphalia
      • Essen, North Rhine-Westphalia, Alemanha, 45147
        • Recrutamento
        • University Hospital Essen
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • 18 years of age or older
  • Scheduled to undergo a first allogeneic hematopoietic stem cell transplantation (HSCT) with an inpatient hospital stay for a myeloid blood disorder
  • Cleared by the treating physician to participate in physical exercise before and after HSCT
  • Able to move around independently or with the use of an assistive device
  • Sufficient German language skills to understand the study information and exercise instructions, report symptoms, and complete the study questionnaires
  • Able to understand the study and provide written informed consent
  • Able to take part in the supervised online exercise sessions, including access to an internet-enabled device and a sufficiently stable internet connection

Exclusion Criteria:

  • An acute medical condition that makes physical exercise unsafe, as determined by the treating physician
  • Cognitive or mental health problems that prevent safe participation in the exercise program or understanding of the study procedures
  • Pregnancy or plans to become pregnant during the 12-week study intervention
  • Insufficient German language skills to participate safely in the exercise program or to complete the study assessments
  • Participation in another structured exercise or training program that could affect the study results. Normal daily activities and self-directed physical activity are allowed.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Cuidados de suporte
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Exercise Intervention Group

Participants assigned to this arm receive the 12-week RESTART exercise intervention in addition to usual medical, nursing, and supportive care after allogeneic hematopoietic stem cell transplantation.

Participants receive a 12-week individualized, multimodal exercise intervention in addition to usual care, consisting of three sessions per week: one individual in-person session (approximately 60 minutes), one live supervised online session (approximately 45 minutes), and one independently performed home-based session (approximately 30 minutes). Across the intervention, exercise content may include aerobic, resistance, mobility, balance, coordination, and cognitive-motor exercises. Training duration, intensity, exercise selection, and volume are individually adapted to the participant's medical condition, physical capacity, treatment-related symptoms, daily condition, and personal goals. In-person and online sessions are supervised by qualified exercise therapists; home-based exercises are individually selected and explained in advance, with an emphasis on low-risk, easily controllable exercises that can be performed safely without direct supervision.

Sem intervenção: Usual Care Control Group

Participants assigned to this arm receive usual medical, nursing, and supportive care during the 12-week control period. No additional RESTART exercise intervention is provided during this period. Medically indicated care and self-directed physical activity are not restricted.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Change in Executive Function Composite Score From Hospital Discharge to 13 Weeks After Discharge
Prazo: Hospital discharge (T1) and 13 weeks after hospital discharge, following the 12-week intervention or control period (T2)

Executive function is assessed using a standardized composite score derived from performance on the Flanker Task (reaction time, error rate, and flanker effect), Trail Making Test Part B (completion time), and Digit Span Backward (score). Individual test measures are standardized and combined into a composite score representing executive function, including inhibitory control, cognitive flexibility, and working memory. Test measures are transformed as needed so that higher composite scores indicate better executive function.

Hospital discharge (T1) and 13 weeks after hospital discharge, following the 12-week intervention or control period (T2)

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Change in Global Cognitive Function Assessed by the Montreal Cognitive Assessment (MoCA)
Prazo: Pre-HSCT (T0), hospital discharge (T1), and 13 weeks after hospital discharge (T2)

Global cognitive function is assessed using the Montreal Cognitive Assessment (MoCA). The total score ranges from 0 to 30, with higher scores indicating better global cognitive function.

Pre-HSCT (T0), hospital discharge (T1), and 13 weeks after hospital discharge (T2)
Change in Reaction Time Assessed by the OORTT 4 Positions Reaction Times
Prazo: Hospital discharge (T1) and 13 weeks after hospital discharge (T2)

Reaction time is assessed using the OORTT 4 Positions Reaction Times and reported in milliseconds (ms). Lower values indicate faster responses.

Hospital discharge (T1) and 13 weeks after hospital discharge (T2)
Change in Inhibitory Control Assessed by the Flanker Task
Prazo: Pre-HSCT (T0), hospital discharge (T1), and 13 weeks after hospital discharge (T2)

Inhibitory control is assessed using the Flanker Task. The primary task-specific outcome is the reaction-time-based flanker interference effect, calculated as the difference in mean reaction time between incongruent and congruent trials and expressed in milliseconds (ms). A smaller interference effect indicates better inhibitory control. Reaction time and error rate are additionally recorded as task performance parameters.

Pre-HSCT (T0), hospital discharge (T1), and 13 weeks after hospital discharge (T2)
Change in Cognitive Flexibility Assessed by Trail Making Test Part B
Prazo: Hospital discharge (T1) and 13 weeks after hospital discharge (T2)

Cognitive flexibility and task switching are assessed using Trail Making Test Part B. The outcome is completion time in seconds, with shorter completion times indicating better performance.

Hospital discharge (T1) and 13 weeks after hospital discharge (T2)
Change in Working Memory Assessed by Digit Span Backward
Prazo: Hospital discharge (T1) and 13 weeks after hospital discharge (T2)

Working memory is assessed using Digit Span Backward. The outcome is the total score according to the standardized scoring procedure, with higher scores indicating better working-memory performance.

Hospital discharge (T1) and 13 weeks after hospital discharge (T2)
Change in Static Balance Assessed by the 4-Stage Balance Test
Prazo: Pre-HSCT (T0), hospital discharge (T1), and 13 weeks after hospital discharge (T2)

Static balance is assessed using the 4-Stage Balance Test, consisting of four progressively more difficult standing positions. Each position is held for up to 10 seconds. The outcome is the highest stage successfully maintained for 10 seconds, ranging from 0 to 4, with higher values indicating better static balance.

Pre-HSCT (T0), hospital discharge (T1), and 13 weeks after hospital discharge (T2)
Change in Maximum Isometric Handgrip Strength
Prazo: Pre-HSCT (T0), hospital discharge (T1), and 13 weeks after hospital discharge (T2)

Maximum isometric handgrip strength is assessed using the CITEC Handheld Dynamometer Advanced Kit and expressed as peak force in Newtons (N). Three valid maximal trials are performed with the dominant hand, and the highest peak force is used for analysis. Higher values indicate greater handgrip strength.

Pre-HSCT (T0), hospital discharge (T1), and 13 weeks after hospital discharge (T2)
Change in isometric knee flexor strength (hand-held dynamometry)
Prazo: Pre-HSCT (T0), hospital discharge (T1), and 13 weeks after hospital discharge (T2)

Isometric knee flexor strength is assessed using the CITEC Handheld Dynamometer Advanced Kit and expressed as peak force in Newtons (N). Three valid maximal isometric knee extension trials are performed with the dominant leg, and the mean peak force of the three trials is used for analysis. Higher values indicate greater knee extensor strength.

Pre-HSCT (T0), hospital discharge (T1), and 13 weeks after hospital discharge (T2)
Change in Functional Lower-Extremity Performance Assessed by the 30-Second Sit-to-Stand Test
Prazo: Pre-HSCT (T0), hospital discharge (T1), and 13 weeks after hospital discharge (T2)

Functional lower-extremity performance is assessed using the 30-Second Sit-to-Stand Test. The outcome is the number of complete sit-to-stand repetitions performed within 30 seconds. Higher values indicate better functional performance.

Pre-HSCT (T0), hospital discharge (T1), and 13 weeks after hospital discharge (T2)
Change in Peak Work Rate Assessed by the Steep Ramp Test
Prazo: Pre-HSCT (T0), hospital discharge (T1), and 13 weeks after hospital discharge (T2)

Exercise capacity is assessed using the Steep Ramp Test performed on a cycle ergometer. The outcome is peak work rate (WRpeak), expressed in watts (W), achieved at the end of the test. Higher values indicate greater exercise capacity.

Pre-HSCT (T0), hospital discharge (T1), and 13 weeks after hospital discharge (T2)
Change in Perceived Cognitive Impairment Assessed by the FACT-Cog Version 3
Prazo: Hospital discharge (T1), 13 weeks (T2), 6 months (T3), and 12 months (T4) after hospital discharge

Perceived cognitive impairment is assessed using the Perceived Cognitive Impairments (PCI) subscale of the Functional Assessment of Cancer Therapy-Cognitive Function, Version 3 (FACT-Cog v3). The PCI score ranges from 0 to 72, with higher scores indicating better self-reported cognitive function and fewer perceived cognitive impairments.

Hospital discharge (T1), 13 weeks (T2), 6 months (T3), and 12 months (T4) after hospital discharge
Change in Global Health Status and Quality of Life Assessed by the EORTC QLQ-C30
Prazo: Hospital discharge (T1), 13 weeks (T2), 6 months (T3), and 12 months (T4) after hospital discharge

Global health status and quality of life are assessed using the Global Health Status/Quality of Life scale of the EORTC QLQ-C30. Scores are transformed to a scale from 0 to 100 according to the EORTC scoring manual, with higher scores indicating better global health status and quality of life.

Hospital discharge (T1), 13 weeks (T2), 6 months (T3), and 12 months (T4) after hospital discharge
Change in General Self-Efficacy Assessed by the ASKU
Prazo: Hospital discharge (T1), 13 weeks (T2), 6 months (T3), and 12 months (T4) after hospital discharge

General self-efficacy is assessed using the Allgemeine Selbstwirksamkeit Kurzskala (ASKU). The mean score ranges from 1 to 5, with higher scores indicating greater general self-efficacy.

Hospital discharge (T1), 13 weeks (T2), 6 months (T3), and 12 months (T4) after hospital discharge
Change in Depressive Symptoms Assessed by the Patient Health Questionnaire-9 (PHQ-9)
Prazo: Hospital discharge (T1), 13 weeks (T2), 6 months (T3), and 12 months (T4) after hospital discharge

Depressive symptoms are assessed using the 9-item Patient Health Questionnaire (PHQ-9). Total scores range from 0 to 27, with higher scores indicating greater depressive symptom severity.

Hospital discharge (T1), 13 weeks (T2), 6 months (T3), and 12 months (T4) after hospital discharge
Change in Patient-Reported Symptoms Assessed by the PRO-CTCAE
Prazo: Hospital discharge (T1), 13 weeks (T2), 6 months (T3), and 12 months (T4) after hospital discharge

Symptoms and treatment-related adverse effects are assessed using pre-specified items from the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Selected symptom attributes, including frequency, severity, and interference with daily activities, are analyzed at the item level according to the respective PRO-CTCAE response scales. Each attribute is scored from 0 to 4, with higher scores indicating greater symptom frequency, severity, or interference and therefore a worse outcome. No overall summary score is calculated.

Hospital discharge (T1), 13 weeks (T2), 6 months (T3), and 12 months (T4) after hospital discharge
Change in Leisure-Time Physical Activity Assessed by the Godin Leisure-Time Exercise Questionnaire
Prazo: Pre-HSCT (T0), weekly during hospitalization, hospital discharge (T1), weekly during the 12-week intervention/control period, 13 weeks (T2), 6 months (T3), and 12 months (T4) after hospital discharge

Leisure-time physical activity is assessed using the Godin Leisure-Time Exercise Questionnaire. The primary metric is the Leisure Score Index, calculated as (9 × weekly frequency of strenuous activity) + (5 × weekly frequency of moderate activity) + (3 × weekly frequency of mild activity). The Leisure Score Index has a minimum value of 0 and no predefined maximum value because the reported weekly activity frequencies are not capped. Higher scores indicate greater leisure-time physical activity and therefore a better outcome.

Pre-HSCT (T0), weekly during hospitalization, hospital discharge (T1), weekly during the 12-week intervention/control period, 13 weeks (T2), 6 months (T3), and 12 months (T4) after hospital discharge
Change in Sitting Time Assessed Using Items From the International Physical Activity Questionnaire (IPAQ)
Prazo: Pre-HSCT (T0), weekly during hospitalization, hospital discharge (T1), weekly during the 12-week intervention/control period, 13 weeks (T2), 6 months (T3), and 12 months (T4) after hospital discharge

Sedentary behavior is assessed using selected sitting-time items from the International Physical Activity Questionnaire (IPAQ). The outcome is average daily sitting time, expressed in minutes per day, with a theoretical range from 0 to 1,440 minutes per day. Higher values indicate more time spent sitting and therefore a worse outcome.

Pre-HSCT (T0), weekly during hospitalization, hospital discharge (T1), weekly during the 12-week intervention/control period, 13 weeks (T2), 6 months (T3), and 12 months (T4) after hospital discharge
Social and Occupational Reintegration After Hospital Discharge
Prazo: 13 weeks (T2), 6 months (T3), and 12 months (T4) after hospital discharge

Reintegration is assessed using the study-specific RESTART Reintegration Questionnaire following allogeneic hematopoietic stem cell transplantation (HSCT). Items on return to everyday life, social integration, and ability to manage important daily activities are rated from 1 ("not at all") to 5 ("completely"); higher scores indicate better reintegration. Reintegration into employment, education, studies, or a comparable regular activity is rated from 1 to 5, with higher scores indicating better reintegration; 0 indicates "not applicable" and is not interpreted as a lower score. Current employment/education status is assessed categorically. An open-ended item assesses factors facilitating or hindering reintegration. Items are analyzed separately; no overall summary score is calculated.

13 weeks (T2), 6 months (T3), and 12 months (T4) after hospital discharge
Occurrence and Severity of Graft-Versus-Host Disease
Prazo: Hospital discharge (T1) through 12 months after hospital discharge (T4)

Acute and/or chronic graft-versus-host disease (GvHD) is obtained from routine clinical records. GvHD status at hospital discharge and occurrence or progression during follow-up are documented, including clinically assessed grade or stage where applicable.

Hospital discharge (T1) through 12 months after hospital discharge (T4)
Incidence of Infections
Prazo: Hospital discharge (T1) through 12 months after hospital discharge (T4)

Clinically documented infections occurring after hospital discharge are obtained from routine clinical records. The number of infections per participant is recorded and infections are additionally characterized by type and severity.

Hospital discharge (T1) through 12 months after hospital discharge (T4)
Number of Rehospitalizations
Prazo: Hospital discharge (T1) through 12 months after hospital discharge (T4)

The number of rehospitalizations occurring after hospital discharge is obtained from routine clinical records. Duration and reason for rehospitalization are additionally documented.

Hospital discharge (T1) through 12 months after hospital discharge (T4)

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
Change in White Blood Cell Count
Prazo: Pre-HSCT (T0) through 12 months after hospital discharge (T4), as available from routine clinical care

White blood cell count is obtained from routine clinical laboratory data and expressed as ×10⁹/L. Longitudinal changes are evaluated across the available study time points.

Pre-HSCT (T0) through 12 months after hospital discharge (T4), as available from routine clinical care
Change in Absolute Neutrophil Count
Prazo: Pre-HSCT (T0) through 12 months after hospital discharge (T4), as available from routine clinical care

Absolute neutrophil count is obtained from routine clinical laboratory data and expressed as ×10⁹/L. Longitudinal changes are evaluated across the available study time points.

Pre-HSCT (T0) through 12 months after hospital discharge (T4), as available from routine clinical care
Change in Absolute Lymphocyte Count
Prazo: Pre-HSCT (T0) through 12 months after hospital discharge (T4), as available from routine clinical care

Absolute lymphocyte count is obtained from routine clinical laboratory data and expressed as ×10⁹/L. Longitudinal changes are evaluated across the available study time points.

Pre-HSCT (T0) through 12 months after hospital discharge (T4), as available from routine clinical care
Change in Platelet Count
Prazo: Pre-HSCT (T0) through 12 months after hospital discharge (T4), as available from routine clinical care

Platelet count is obtained from routine clinical laboratory data and expressed as ×10⁹/L. Longitudinal changes are evaluated across the available study time points.

Pre-HSCT (T0) through 12 months after hospital discharge (T4), as available from routine clinical care
Change in Hemoglobin Concentration
Prazo: Pre-HSCT (T0) through 12 months after hospital discharge (T4), as available from routine clinical care

Hemoglobin concentration is obtained from routine clinical laboratory data and expressed in g/dL. Longitudinal changes are evaluated across the available study time points.

Pre-HSCT (T0) through 12 months after hospital discharge (T4), as available from routine clinical care
Change in C-Reactive Protein Concentration
Prazo: Pre-HSCT (T0) through 12 months after hospital discharge (T4), as available from routine clinical care

C-reactive protein (CRP) concentration is obtained from routine clinical laboratory data, where available, and expressed in mg/L. Longitudinal changes are evaluated across the available study time points.

Pre-HSCT (T0) through 12 months after hospital discharge (T4), as available from routine clinical care
Measurable Residual Disease Status
Prazo: Pre-HSCT (T0) through 12 months after hospital discharge (T4), as available from routine clinical care

Measurable residual disease (MRD) status is obtained from routine clinical assessments using disease-specific methods and documented as positive or negative. Quantitative results are additionally recorded where available.

Pre-HSCT (T0) through 12 months after hospital discharge (T4), as available from routine clinical care
Donor Chimerism
Prazo: From allogeneic HSCT through 12 months after hospital discharge (T4), as available from routine clinical care

Donor chimerism is obtained from routine clinical assessments following allogeneic HSCT and expressed as percentage donor chimerism, where available.

From allogeneic HSCT through 12 months after hospital discharge (T4), as available from routine clinical care
Time to Hematologic Recovery
Prazo: From allogeneic HSCT through hematologic recovery, as documented during follow-up through 12 months after hospital discharge (T4)

Hematologic recovery following allogeneic HSCT is assessed from routine clinical laboratory data. Time to hematologic recovery is documented in days according to the definitions used in routine transplant care.

From allogeneic HSCT through hematologic recovery, as documented during follow-up through 12 months after hospital discharge (T4)
Exercise Intervention Adherence Rate
Prazo: During the 12-week intervention period

Adherence is calculated as the percentage of prescribed RESTART exercise sessions completed by participants assigned to the exercise intervention group. Higher percentages indicate greater adherence.

During the 12-week intervention period
Number of Completed Exercise Sessions
Prazo: During the 12-week intervention period

The total number of completed RESTART exercise sessions is recorded for participants assigned to the exercise intervention group. Sessions are additionally categorized as individual in-person, supervised online, or home-based sessions.

During the 12-week intervention period
Exercise Training Frequency
Prazo: During the 12-week intervention period

Exercise training frequency is calculated as the mean number of completed RESTART exercise sessions per week among participants assigned to the exercise intervention group.

During the 12-week intervention period
Participant Dropout Rate
Prazo: From enrollment through 12 months after hospital discharge (T4)

The dropout rate is calculated as the proportion of enrolled participants who discontinue study participation before completion of the final follow-up assessment. Reasons for dropout are documented descriptively.

From enrollment through 12 months after hospital discharge (T4)
Number of Participants With Adverse Events During the Intervention or Control Period
Prazo: Hospital discharge (T1) through 13 weeks after hospital discharge (T2)

The number of participants experiencing at least one adverse event during the intervention or control period is recorded. Adverse events are additionally characterized by type, severity, and possible relationship to the exercise intervention.

Hospital discharge (T1) through 13 weeks after hospital discharge (T2)
Number of Participants With Serious Adverse Events During the Intervention or Control Period
Prazo: Hospital discharge (T1) through 13 weeks after hospital discharge (T2)

The number of participants experiencing at least one serious adverse event during the intervention or control period is recorded. Serious adverse events are additionally characterized by type, severity, and possible relationship to the exercise intervention.

Hospital discharge (T1) through 13 weeks after hospital discharge (T2)

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Investigador principal: Miriam Goette, PD Dr. rer. medic., University Hospital, Essen

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

1 de novembro de 2026

Conclusão Primária (Estimado)

30 de setembro de 2029

Conclusão do estudo (Estimado)

1 de julho de 2030

Datas de inscrição no estudo

Enviado pela primeira vez

30 de setembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

30 de setembro de 2026

Primeira postagem (Real)

9 de outubro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

18 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

17 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • 26-13152-BO

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .